NASDAQ · INMD
Healthcare · Medical - Devices
$13.97
Down-$0.08 (-0.57%)
Updated Oct 25, 2026, 1:08 AM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · INMD
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 23, 2026
INMD closed at $13.97 after 20 trading sessions, down 1.65% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | $14.00 | $14.05 | $13.93 | $13.97 | 420.74K |
| Oct 22, 2026 | $14.05 | $14.14 | $14.01 | $14.05 | 805.62K |
| Oct 21, 2026 | $14.08 | $14.15 | $13.97 | $14.03 | 424.26K |
| Oct 20, 2026 | $14.14 | $14.21 | $14.09 | $14.14 | 379.1K |
| Oct 19, 2026 | $14.12 | $14.265 | $14.065 | $14.07 | 399.74K |
| Oct 16, 2026 | $14.32 | $14.35 | $14.14 | $14.16 | 417.15K |
| Oct 15, 2026 | $14.37 | $14.475 | $14.29 | $14.32 | 633.86K |
| Oct 14, 2026 | $14.27 | $14.295 | $14.20 | $14.28 | 337.65K |
| Oct 13, 2026 | $14.40 | $14.50 | $14.295 | $14.305 | 428.63K |
| Oct 12, 2026 | $14.22 | $14.31 | $14.18 | $14.30 | 435.53K |
| Oct 9, 2026 | $14.05 | $14.225 | $14.05 | $14.21 | 289.94K |
| Oct 8, 2026 | $14.00 | $14.095 | $13.8614 | $14.08 | 365.49K |
| Oct 7, 2026 | $13.91 | $14.045 | $13.895 | $14.01 | 511.98K |
| Oct 6, 2026 | $14.14 | $14.1725 | $13.95 | $13.99 | 538.13K |
| Oct 5, 2026 | $14.07 | $14.19 | $14.06 | $14.13 | 497.75K |
| Oct 2, 2026 | $14.06 | $14.15 | $13.985 | $14.09 | 616.36K |
| Oct 1, 2026 | $14.08 | $14.18 | $13.9705 | $14.05 | 561.66K |
| Sep 30, 2026 | $14.21 | $14.215 | $14.11 | $14.17 | 378.73K |
| Sep 29, 2026 | $14.192 | $14.23 | $14.085 | $14.22 | 362.74K |
| Sep 28, 2026 | $14.26 | $14.29 | $14.19 | $14.205 | 201.74K |
The latest Smart Investors Daily articles mentioning INMD.
Company
Market Activity
Research & News
INMD research
Company profile and research snapshot.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 7, 2026 | Barclays | Overweight | — |
| May 7, 2026 | Baird | Neutral | — |
| Dec 17, 2025 | Canaccord Genuity | Hold | — |
| Nov 6, 2025 | UBS | Neutral | — |
| Oct 10, 2025 | Needham | Hold | — |
No generated briefing is available yet.
Yahoo · Oct 19, 2026
NEW YORK, October 19, 2026--Steel Partners Holdings L.P. (together with its affiliates, "Steel"), a significant, long-standing shareholder of InMode Ltd. ("InMode" or the "Company") (Nasdaq: INMD), today issued an open letter to all InMode stakeholders. The full text of the letter is below.
Benzinga · Oct 19, 2026
To All InMode Stakeholders:Steel Partners Holdings L.P. (together with its affiliates, "Steel") is a significant, long-standing shareholder of InMode Ltd. On July 9, 2026, we proposed to acquire up to 100% of
Yahoo · Oct 13, 2026
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter of 2026 before the Nasdaq market opens on Wednesday, November 11, 2026.
Benzinga · Oct 13, 2026
InMode (NASDAQ:INMD) sees Q3 sales of $91.800 million-$92.000 million vs $91.600 million analyst estimate.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INMD.
